Avecho Biotechnology Limited AVE
ASX · Australia · Health Technology
AUD 0.0200+0.00 (+11.11%)
Market open· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Avecho Biotechnology CEO Paul Gavin talked with Proactive at the ASX Small and Mid-Cap Conference about its Phase 3 study into insomnia and its proprietary drug delivery system. Avecho Biotechnology Limited develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM®). TPM is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients. Avecho’s lead asset is a proprietary cannabidio
Avecho Biotechnology Limited (ASX: AVE) ("Avecho" or "the Company") has announced it will continue with recruitment for its world-first Phase III insomnia program following a positive interim analysis evaluating its TPM®-enhanced cannabidiol (CBD) capsule.
Avecho Biotechnology Ltd (ASX:AVE, OTC:AVEFF, FRA:OEZ) has completed the treatment phase for the final patient required for the planned interim analysis of its pivotal Phase III insomnia trial. The interim cohort includes 244 participants, who were randomised across 3 groups to receive...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.